-
The incidence of adverse outcome in donors after living-donor liver transplantation: A meta-analysis of 60,829 donors. Liver Transpl. (IF 4.6) Pub Date : 2023-11-29 Jieling Xiao,Rebecca Wenling Zeng,Wen Hui Lim,Darren Jun Hao Tan,Jie Ning Yong,Clarissa Elysia Fu,Phoebe Tay,Nicholas Syn,Christen En Ya Ong,Elden Yen Hng Ong,Charlotte Hui Chung,Shi Yan Lee,Jia Hong Koh,Margaret Teng,Sameer Prakash,Eunice Xx Tan,Karn Wijarnpreecha,Anand V Kulkarni,Ken Liu,Pojsakorn Danpanichkul,Daniel Q Huang,Mohammad Shadab Siddiqui,Cheng Han Ng,Alfred Wei Chieh Kow,Mark D Muthiah
BACKGROUND The scarcity of liver grafts has prompted developments in living donor liver transplantations (LDLT) with previous literature illustrating similar outcomes in recipients compared to deceased donor transplants. However, significant concerns regarding living donor morbidity and mortality have yet to be examined comprehensively. This study aims to provide estimates of the incidence of various
-
Robotic and laparoscopic right lobe living donation compared to the open approach. a multicenter study on 1194 donor hepatectomies. Liver Transpl. (IF 4.6) Pub Date : 2023-11-29 Roberto Ivan Troisi,Hwui-Dong Cho,Mariano Cesare Giglio,Jinsoo Rhu,Jai Young Cho,Kazuanri Sasaki,Dai Hoon Han,David Kwon,Ho-Seong Han,Po-Da Chen,Yao-Ming Wu,Gi Hong Choi,Gyu Sung Choi,Ki-Hun Kim
Due to the success of minimally invasive liver surgery, laparoscopic and robotic minimally invasive donor hepatectomies (MIDH) are increasingly performed worldwide. We conducted a retrospective, multicentre, propensity score-matched (PSM) analysis on right lobe MIDH by comparing the robotic, laparoscopic, and open approaches to assess the feasibility, safety, and early outcomes of MIDHs. From January
-
Improved outcomes of kidney-after-liver transplantation after the implementation of the safety net policy. Liver Transpl. (IF 4.6) Pub Date : 2023-11-29 Rose Mary Attieh,Ramez M Ibrahim,Peter Ghali,Andrew Keaveny,Kristopher Croome,David Hodge,Launia White,Hani M Wadei
BACKGROUND The number of kidney after liver transplants (KALT) increased after the implementation of the UNOS safety net policy but the effects of the policy on KALT outcomes remain unknown. METHODS Using the UNOS database, we identified KALT between 60 and 365 days from liver transplant (LT) from 1/1/2010 to 12/31/2020. The main outcome was 1- and 3-year patient, liver and kidney graft survival. Secondary
-
Outcomes using steatotic liver grafts: Will machines score the final goal? Liver Transpl. (IF 4.6) Pub Date : 2023-11-28 Giulia Pagano,Yilliam Fundora,Gonzalo Crespo
-
Outcome of living-donor liver transplantation for patients older than age 70 years, with respect to preserved performance status and graft quality. Liver Transpl. (IF 4.6) Pub Date : 2023-11-28 Takeo Toshima,Noboru Harada,Shinji Itoh,Yuuki Nakayama,Katsuya Toshida,Takahiro Tomiyama,Yukiko Kosai-Fujimoto,Takahiro Tomino,Shohei Yoshiya,Yoshihiro Nagao,Hiroto Kayashima,Tomoharu Yoshizumi
-
Weighing in on organ allocation for tweens. Liver Transpl. (IF 4.6) Pub Date : 2023-11-28 Elise Kang,Steven Lobritto,Mercedes Martinez
-
Freedom isn't free: Assessing the risks and benefits of steroid-free immunosuppression regimens in pediatric liver transplantation in a real world setting. Liver Transpl. (IF 4.6) Pub Date : 2023-11-28 Anna L Peters,Emily R Perito
-
Reexamining "Psychosocial clearance": A procedural framework for psychosocial evaluation in liver transplantation. Liver Transpl. (IF 4.6) Pub Date : 2023-11-28 Gerald Scott Winder,Anne C Fernandez,Ponni V Perumalswami,Jessica L Mellinger,Erin G Clifton
Psychosocial and "non-medical" phenomena are commonly encountered in liver transplantation (LT) evaluations. They are simultaneously crucial decision-making factors and some of the most difficult and controversial clinical matters clinicians confront. Epidemiology, societal trends, and the preponderance of psychological and behavioral factors underpinning common end-stage liver diseases ensure that
-
Transplant selection simulation: Liver transplantation for alcohol-associated hepatitis. Liver Transpl. (IF 4.6) Pub Date : 2023-11-28 Gene Y Im,Aparna Goel,Sumeet Asrani,Ashwani K Singal,Anji Wall,Courtney B Sherman
Liver transplantation (LT) for alcohol-associated hepatitis (AH) remains controversial due to concerns about candidate selection subjectivity, post-LT alcohol relapse and the potential exacerbation of LT disparities. Our aim was to design, perform and examine the results of a simulated selection of candidates for LT for AH. Medical histories, psychosocial profiles and scores, and outcomes of four simulation
-
Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals. Liver Transpl. (IF 4.6) Pub Date : 2023-11-09 Harmeet Malhi,Robert S Brown,Joseph K Lim,Nancy Reau,Elliot B Tapper,Carmen Chak-Lui Wong,Gregory J Gores
-
Does liraglutide alleviates inflammation in brain-dead donors? A randomized clinical trial. Liver Transpl. (IF 4.6) Pub Date : 2023-11-09 Geisiane Custódio,Andrew Maykon Massutti,Mauro Rafael da Igreja,Natália Emerim Lemos,Daisy Crispim,Fernanda Visioli,Victor de Mello Palma,Cristiane Bauermann Leitão,Tatiana Helena Rech
BACKGROUND Brain death triggers an inflammatory cascade that damages organs before procurement, adversely affecting the quality of grafts. This randomized clinical trial aimed to compare the efficacy of liraglutide compared to placebo in attenuating brain death-induced inflammation, endoplasmic reticulum stress, and oxidative stress. METHODS We conducted a double-blinded, placebo-controlled, randomized
-
Assessing reliability and validity of SIPAT and opportunities for improvement: A single-center cohort study. Liver Transpl. (IF 4.6) Pub Date : 2023-11-09 Jennifer M Perry,Sasha Deutsch-Link,Elizabeth Marfeo,Marina Serper,Keren Ladin
Psychosocial assessment is a standard component of patient evaluations for transplant candidacy. The Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) is a widely used measure to assess psychosocial risk for transplant. However, there are questions regarding the SIPAT's reliability and validity. We examined the SIPAT's psychometric performance and its impact on equitable access to
-
Reply: How does ex vivo liver perfusion help improve the outcomes of liver transplantation in donation after cardiac death (DCD) donors? Liver Transpl. (IF 4.6) Pub Date : 2023-11-09 Tobenna Ibeabuchi,Eric Li,Therese Bittermann,Nadim Mahmud,Peter L Abt
-
Making the best use of testing for blood phosphatidylethanol. Liver Transpl. (IF 4.6) Pub Date : 2023-11-08 Jessica A Musto,Margarita N German,Michael R Lucey
-
Immunosuppression minimization is safe and associated with good long-term success in pediatric recipients of liver transplant. Liver Transpl. (IF 4.6) Pub Date : 2023-11-08 Catherine A Chapin,Bridget Whitehead,Victoria Shakhin,Sarah A Taylor,Alyssa Kriegermeier,Saeed Mohammad,Estella M Alonso
Immunosuppression reduction after liver transplant is an important strategy to mitigate long-term medication side effects. We describe our center's experience with immunosuppression minimization to once-daily calcineurin inhibitor dosing. Success was defined as continuing daily calcineurin inhibitor monotherapy with normal transaminases and no rejection. We performed a retrospective review of eligible
-
Liver transplant evaluation redux: Hope for reconsidering previously declined candidates with alcohol-associated liver disease. Liver Transpl. (IF 4.6) Pub Date : 2023-11-08 Gerald Scott Winder,Jessica L Mellinger
-
Alcohol use disorder in alcohol-associated liver disease: Two sides of the same coin. Liver Transpl. (IF 4.6) Pub Date : 2023-11-08 Ashwani K Singal,Lorenzo Leggio,Andrea DiMartini
Alcohol-associated liver disease (ALD) has emerged as the leading indication for liver transplantation (LT) worldwide, with 40% of LTs in the United States performed for ALD in 2019. The ALD-related health care burden accelerated during the COVID-19 pandemic, especially in young individuals. Alcohol use disorder (AUD), which focuses on the negative effects of alcohol on psychosocial, physical, and
-
Transplant center variability in utilizing nonstandard donors and its impact on the transplantation of patients with lower MELD scores. Liver Transpl. (IF 4.6) Pub Date : 2023-10-31 David S Goldberg,Gregory J McKenna
There is a subset of patients with lower MELD scores who are at substantial risk of waitlist mortality. In order to transplant such patients, transplant centers must utilize "nonstandard" donors (eg, living donors, donation after circulatory death), which are traditionally offered to those patients who are not at the top of the waitlist. We used Organ Procurement and Transplantation data to evaluate
-
Weight to go!-Glucagon-like peptide 1 receptor agonists in liver transplant recipients. Liver Transpl. (IF 4.6) Pub Date : 2023-10-30 Abhishek Shenoy,Patricia P Bloom
-
Letter to the Editor: How does ex vivo liver perfusion help improve the outcomes of liver transplantation in donation after cardiac death donors? Liver Transpl. (IF 4.6) Pub Date : 2023-10-30 Kenji Okumura,Abhay Dhand,Ryosuke Misawa,Seigo Nishida
-
A Modified liver donor risk index for pediatric liver transplant recipients. Liver Transpl. (IF 4.6) Pub Date : 2023-10-30 Maya Guhan,Ashley Montgomery,Ron Varghese,Abbas Rana
The Liver Donor Risk Index (LDRI) was developed by Feng et. al. to predict the quality of donor liver allografts. However, there is currently no literature documenting the application and efficacy of Feng's LDRI specifically for the pediatric population. The goal of our study is to apply Feng's LDRI to our study population as well as develop a pediatric-specific LDRI. De-identified data from the United
-
The prognostic implications of early-stage AKI: Defining the threshold for concern. Liver Transpl. (IF 4.6) Pub Date : 2023-10-30 Adam C Winters,Justin Belcher
-
Psychosocial evaluation of living liver donors-State of current practices in the United States. Liver Transpl. (IF 4.6) Pub Date : 2023-10-23 Paula C Zimbrean,Susan Rubman,Oya Andacoglu,Darshit Bakhai,Erin Clifton,Yanhong Deng,Mona Doshi,Juliet Emamaullee,Geliang Gan,Rachel Holmes,Lana Jaber,Whitney E Jackson,Michael Joyce,Roberto Kalil,Vineeta Kumar,Jennie Laflen,Krista L Lentine,Rohini Prashar,Gerald S Winder,Anju Yadav,AnnMarie Liapakis
We surveyed living donor liver transplant programs in the United States to describe practices in the psychosocial evaluation of living donors focused on (1) composition of psychosocial team; (2) domains, workflow, and tools of the psychosocial assessment; (3) absolute and relative mental health-related contraindications to donation; and (4) postdonation psychosocial follow-up. We received 52 unique
-
Factors associated with receiving a liver transplant from deceased donors located far from the transplant hospital. Liver Transpl. (IF 4.6) Pub Date : 2023-10-20 Neha P Godbole,David S Goldberg
-
Do not underestimate the impact of hepatic hydrothorax on survival before and after liver transplant. Liver Transpl. (IF 4.6) Pub Date : 2023-10-20 Karen L Krok
-
Reply: The urgent need for consensus around organ donation after assisted dying. Liver Transpl. (IF 4.6) Pub Date : 2023-10-19 Juan Glinka,Evelyn Waugh,Anton Skaro
-
Management of patients with cirrhosis in the emergency department: Implications for hospitalization outcomes. Liver Transpl. (IF 4.6) Pub Date : 2023-10-19 Sandeep Sikerwar,Sohrab Zand,Peter Steel,Arun Jesudian
-
Impact of implementation of national liver review board on liver allocation among patients with primary sclerosing cholangitis. Liver Transpl. (IF 4.6) Pub Date : 2023-10-17 Smriti R Kumar,Cynthia Levy,David Goldberg
-
The impact of health literacy on adolescent and young adult pediatric liver transplant recipients. Liver Transpl. (IF 4.6) Pub Date : 2023-10-09 Prerana Baranwal,Mihika Sathe,Steven J Lobritto,Jennifer Vittorio
Pediatric liver transplant recipients have increased rates of morbidity and mortality following transfer to adult health care providers. The role of health literacy (HL) has not been adequately assessed in this population and may be an unrecognized barrier to successful health care transition. We sought to determine the impact of HL for patients and their caregivers on measures of transition readiness
-
Reply: ChatGPT and unknown clinical questions about liver transplantation. Liver Transpl. (IF 4.6) Pub Date : 2023-10-09 Miho Akabane,Kazuhiro Iwadoh,Marc L Melcher,Kazunari Sasaki
-
Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin. Liver Transpl. (IF 4.6) Pub Date : 2023-10-09 Ethan M Weinberg,Florence Wong,Hugo E Vargas,Michael P Curry,Khurram Jamil,S Chris Pappas,Pratima Sharma,K Rajender Reddy
Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI), a serious complication of decompensated cirrhosis, has limited therapeutic options and significant morbidity and mortality. Terlipressin improves renal function in some patients with HRS-1, while liver transplantation (LT) is a curative treatment for advanced chronic liver disease. Renal failure post-LT requiring renal replacement therapy (RRT) is
-
Letter to the Editor: ChatGPT and unknown clinical questions about liver transplantation. Liver Transpl. (IF 4.6) Pub Date : 2023-10-09 Amnuay Kleebayoon,Viroj Wiwanitkit
-
Disparities in travel time to liver transplantation centers in the United States. Liver Transpl. (IF 4.6) Pub Date : 2023-10-06 Xiaohan Ying,Walter S Mathis,Peter A Kahn,Arun B Jesudian,Brett E Fortune,Robert S Brown
-
Outcomes of living donor liver transplant recipients receiving grafts with the graft-to-recipient weight ratio less than 0.6%: A matched pair analysis. Liver Transpl. (IF 4.6) Pub Date : 2023-10-04 Hajime Matsushima,Akihiko Soyama,Takanobu Hara,Yasuhiro Maruya,Takuro Fujita,Hajime Imamura,Tomohiko Adachi,Masaaki Hidaka,Susumu Eguchi
We sometimes experience living donor liver transplantation (LDLT) involving very small grafts with graft-to-recipient weight ratio (GRWR) < 0.6% when the actual graft size is smaller than predicted. The outcomes in this situation have not been fully investigated. The present study aimed to determine the graft outcomes of LDLT with GRWR < 0.6%. We retrospectively reviewed 280 cases of adult LDLT performed
-
Autoimmune hepatitis recurrence after liver transplantation: "Les jeux sont faits". Liver Transpl. (IF 4.6) Pub Date : 2023-10-04 Yasmina Chouik,Christophe Corpechot,Claire Francoz,Eleonora De Martin,Olivier Guillaud,Armand Abergel,Mario Altieri,Louise Barbier,Camille Besch,Olivier Chazouillères,Filomena Conti,Sébastien Dharancy,François Durand,Christophe Duvoux,Jean Gugenheim,Jean Hardwigsen,Marie-Noëlle Hilleret,Pauline Houssel-Debry,Nassim Kamar,Anne Minello,Martine Neau-Cransac,Georges-Philippe Pageaux,Sylvie Radenne,Olivier
Autoimmune hepatitis (AIH) may recur after liver transplantation (LT). The aims of this study were to evaluate the incidence and risk factors for recurrent autoimmune hepatitis (rAIH). A multicenter retrospective French nationwide study, including all patients aged ≥16 transplanted for AIH, with at least 1 liver biopsy 1 year after LT, was conducted between 1985 and 2018. Risk factors for rAIH were
-
Outcomes of re-referrals of patients with alcohol-related liver disease who were previously declined for liver transplantation. Liver Transpl. (IF 4.6) Pub Date : 2023-10-02 Ben Cox,Lauren Carrique,Tomasso Di Maira,Isabel Sales,Caitlin Don,A Gomez-Aldana,Dilip Koshy,Susan Abbey,Les Lilly,Cynthia Tsien,Mamatha Bhat,Elmar Jaeckel,Marie-Josee Lynch,Nazia Selzner
BACKGROUND Since 2018, our program has utilized specific psychosocial criteria and a multidisciplinary approach to assess patients for liver transplant due to alcohol-related liver disease (ALD), rather than the 6-month abstinence rule alone. If declined based on these criteria, specific recommendations are provided to patients and their providers regarding goals for re-referral to increase potential
-
Access and outcomes in liver transplant candidates: How and when we measure is as important as what we measure. Liver Transpl. (IF 4.6) Pub Date : 2023-10-02 Michael Kriss
-
Letter to the editor: The "one liver, one artery" approach for marginal grafts. Liver Transpl. (IF 4.6) Pub Date : 2023-10-02 Fabrizio Di Francesco,Roberta Vella,Giorgia Calandrino,Caterina Accardo,Ivan Vella,Salvatore Gruttadauria
-
Plasma exchange, a promising liver support system with still relevant uncertainties. Liver Transpl. (IF 4.6) Pub Date : 2023-10-02 Javier Fernandez,David Toapanta,Miquel Lozano
-
Living donor liver transplantation in the United States for alcohol-associated liver disease and nonalcoholic steatohepatitis: An evaluation in the current era. Liver Transpl. (IF 4.6) Pub Date : 2023-09-29 Rachel E Hirshorn,Douglas E Schaubel,Peter L Abt,K Rajender Reddy,Therese Bittermann
-
Sarcopenic obesity: A new predictor of recipient liver regeneration after living donor liver transplantation? Liver Transpl. (IF 4.6) Pub Date : 2023-09-29 Benjamin E Rosenthal,Therese Bittermann
-
Predicting cardiovascular events after liver transplant: Is CT coronary angiography the noninvasive test we have been looking for? Liver Transpl. (IF 4.6) Pub Date : 2023-09-29 Selena Z Kuo,Monica Tincopa
-
Pediatric sarcopenia: An imperfect science in evolution. Liver Transpl. (IF 4.6) Pub Date : 2023-09-29 Julia M Boster,Shikha S Sundaram
-
Liver transplantation from uncontrolled DCD donors-is there light at the end of the tunnel? Liver Transpl. (IF 4.6) Pub Date : 2023-09-29 Mathias Vidgren,Gabriel C Oniscu
-
Letter to the Editor: The urgent need for consensus around organ donation after assisted dying. Liver Transpl. (IF 4.6) Pub Date : 2023-09-26 Philip Berry,Sreelakshmi Kotha
-
Second thoughts about second opinions for liver transplantation. Liver Transpl. (IF 4.6) Pub Date : 2023-09-26 Gene Y Im
-
Liver ischemia-reperfusion injury: From trigger loading to shot firing. Liver Transpl. (IF 4.6) Pub Date : 2023-09-21 Eric Felli,Emanuele Felli,Edoardo M Muttillo,Takeshi Urade,Giovanni G Laracca,Valerio Giannelli,Simone Famularo,Bernard Geny,Giuseppe M Ettorre,Krista Rombouts,Massimo Pinzani,Michele Diana,Jordi Gracia-Sancho
An ischemia-reperfusion injury (IRI) results from a prolonged ischemic insult followed by the restoration of blood perfusion, being a common cause of morbidity and mortality, especially in liver transplantation. At the maximum of the potential damage, IRI is characterized by 2 main phases. The first is the ischemic phase, where the hypoxia and vascular stasis induces cell damage and the accumulation
-
Role of protein induced by vitamin-K absence-II in transplanted patients with HCC not producing alpha-fetoprotein. Liver Transpl. (IF 4.6) Pub Date : 2023-09-19 Quirino Lai,Takashi Ito,Samuele Iesari,Toru Ikegami,Daniele Nicolini,Zoe Larghi Laureiro,Massimo Rossi,Marco Vivarelli,Tomoharu Yoshizumi,Etsurou Hatano,Jan Lerut
Elevated Protein Induced by Vitamin-K Absence-II (PIVKA-II) has been shown to be an adverse prognostic factor in HCC patients undergoing liver transplantation (LT). No definitive data are available about the impact of PIVKA-II concerning post-LT recurrence in patients not secreting (≤ 20 ng/mL) alpha-fetoprotein (AFP). An observational retrospective study of the East-West HCC-LT consortium is reported
-
Letter to the Editor: The impact of a paracentesis education program among junior doctors. Liver Transpl. (IF 4.6) Pub Date : 2023-09-19 Rajiv Kurup,Melissa Day,Rohit Gupta,James O'Beirne
-
Primary sclerosing cholangitis and other risk factors for post-transplant lymphoproliferative disease after liver transplantation in adults. Liver Transpl. (IF 4.6) Pub Date : 2023-09-13 Bastian N Ruijter,Maarten E Tushuizen,Danny van der Helm,Mitchel Hew,Marjolein Reeven,Ann C T M Vossen,Herold J Metselaar,Ian P J Alwayn,Jeroen Dubbeld,Wojciech G Polak,Bart van Hoek
Post-transplant lymphoproliferative disease (PTLD) is a rare but serious complication of liver transplantation (LT) with morbidity and mortality. The risk factors for PTLD in adults are ill-defined. This study aimed to assess the risk factors for PTLD after LT in adults. All adult LT recipients between 1986 and 2016 from 2 centers in the Netherlands were included, with follow-up until 2020. PTLD was
-
Treatment strategies for hepatic artery complications after pediatric liver transplantation: A systematic review. Liver Transpl. (IF 4.6) Pub Date : 2023-09-13 Weihao Li,Reinoud P H Bokkers,Rudi A J O Dierckx,Henkjan J Verkade,Dewey H Sanders,Ruben de Kleine,Hubert P J van der Doef
This study aimed to evaluate the effectiveness of different treatments for hepatic artery thrombosis (HAT) and hepatic artery stenosis (HAS) after pediatric liver transplantation. We systematically reviewed studies published since 2000 that investigated the management of HAT and/or HAS after pediatric liver transplantation. Studies with a minimum of 5 patients in one of the treatment methods were included
-
Reply: Blocked drain switch-hepatic venous outflow obstruction. Liver Transpl. (IF 4.6) Pub Date : 2023-09-05 Yuzuru Sambommatsu,Yoshitaka Tamura,Taizo Hibi
-
Early steroids after pediatric liver transplantation protect against T-cell-mediated rejection: Results from the ChilSFree study. Liver Transpl. (IF 4.6) Pub Date : 2023-09-05 Imeke Goldschmidt,Evgeny Chichelnitskiy,Juliane Götz,Nicole Rübsamen,André Karch,Veronika Jäger,Deirdre Kelly,Carla Lloyd,Dominique Debray,Muriel Girard,Lorenzo d' Antiga,Angelo di Giorgio,Loreto Hierro,Joana Pawlowska,Maja Klaudel-Dreszler,Valerie McLin,Simona Korff,Christine Falk,Ulrich Baumann
Steroid-free immunosuppression protocols gained popularity in pediatric liver transplantation (pLT) after the introduction of IL-2-receptor blockade for induction therapy. We analyzed the clinical and immunologic outcome data of the multicenter prospective observational ChilSFree study to compare the impact of steroid-free versus steroid-containing immunosuppressive therapy following pLT in a real-life
-
Letter to the Editor: Blocked drain switch-hepatic venous outflow obstruction. Liver Transpl. (IF 4.6) Pub Date : 2023-09-05 Shanshan Guo,Zhixing Jia
-
A model Including standardized weight improved predicting waiting list mortality in adolescent liver transplant candidates: A US national study. Liver Transpl. (IF 4.6) Pub Date : 2023-09-04 Abdel Aziz Shaheen,Steven R Martin,Sahar Khorsheed,Juan G Abraldes
BACKGROUND AND AIMS The model of end-stage liver disease (MELD) score has been employed to identify liver transplantation in adolescents since 2004. However, the optimal model or prioritizing adolescent candidates is uncertain. In our study we aimed at evaluating the value of adding anthropometric variables to liver transplantation allocation models among adolescents. METHODS We conducted a retrospective
-
Small for size syndrome is the predominant form of early allograft dysfunction in living donor liver transplantation. Liver Transpl. (IF 4.6) Pub Date : 2023-08-30 Subash Gupta,Shaleen Agarwal
-
Implementation of a National Liver Review Board for exception requests in the United States: A 2-year monitoring report. Liver Transpl. (IF 4.6) Pub Date : 2023-08-29 Allison J Kwong,Julia Foutz,Matt Cafarella,Scott W Biggins,Neil D Shah,James Eason,Emily R Perito,James Pomposelli,James Trotter
The exception point system for liver allocation in the United States allows for additional waitlist priority for candidates where the Model for End-Stage Liver Disease or Pediatric End-stage Liver Disease does not effectively represent their urgency or need for a transplant. In May 2019, the review process for liver exception cases transitioned from 11 Regional Review Boards (RRBs) to 1 National Liver
-
Cost-effectiveness analysis of interventional liver-directed therapies for downstaging of HCC before liver transplant. Liver Transpl. (IF 4.6) Pub Date : 2023-08-29 Xiao Wu,Allison Kwong,Michael Heller,R Peter Lokken,Nicholas Fidelman,Neil Mehta
Transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) are the 2 most used modalities for patients with HCC while awaiting liver transplant. The purpose of this study is to perform a cost-effectiveness analysis comparing TACE and TARE for downstaging (DS) patients with HCC. A cost-effectiveness analysis was performed comparing TACE and TARE in DS HCC over a 5-year time horizon
-
Semaglutide is effective in achieving weight loss in liver transplant recipients. Liver Transpl. (IF 4.6) Pub Date : 2023-08-29 Kenneth W Chow,Brittney Ibrahim,Kabir Rahal,Ryan H Hsu,Teresa Tan,Katherine Meneses,Sammy Saab
-
Overcoming the hurdles of steatotic grafts in liver transplantation: Insights into survival and prognostic factors. Liver Transpl. (IF 4.6) Pub Date : 2023-08-25 Miho Akabane,Yuki Imaoka,Carlos O Esquivel,Marc L Melcher,Allison Kwong,Kazunari Sasaki
With increasing metabolic dysfunction-associated steatotic liver disease, the use of steatotic grafts in liver transplantation (LT) and their impact on postoperative graft survival (GS) needs further exploration. Analyzing adult LT recipient data (2002-2022) from the United Network for Organ Sharing database, outcomes of LT using steatotic (≥30% macrosteatosis) and nonsteatotic donor livers, donors